John Neylan News Today

Based on Type C guidance requested and received from the U.S. Food and Drug Administration (FDA), Akari announces it is moving forward into design and planning for pivotal Part B of the Phase 3 clinical

-- The FDA has accepted an IND application supporting clinical development of ANG-3070 in IPF -- Phase 1b trial to be initiated to gather tolerability,...

. 10, 2021 06:00 UTCVifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute kidney injury ST. GALLEN, Switzerland & UNIONDALE, N.Y.--(BUSINESS WIRE)-- Regulatory News:This press release features multimedia. View the full release here: https://...

Press release content from Business Wire. The AP news staff was not involved in its creation.

Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211209006035/en/ AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma

Vifor Pharma and Angion announce completion of enrollment in phase-II study of ANG-3777 for cardiac-surgery associated acute kidney injury Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210428005922/en/ Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN), today announced completion of enrollment for Angions AKI-002-15 study, a phase-II trial of ANG-3777 in patients at risk of cardiac-surgery associated acute kidne...

More from AP